Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. - Wikidata - awgldk - TriplyDB

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.

http://www.wikidata.org/entity/Q34621423

about

Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry Rapidly improved determination of metabolites from biological data sets using the high-efficient TransOmics tool.Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus.The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews.IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes.Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.Individualization of chronic hepatitis C treatment according to the host characteristics.Impact of HCV genetic differences on pathobiology of disease.Clinical utility of interleukin-28B testing in patients with genotype 1.Introduction to the genetics and biology of interleukin-28B.Genetics of IL28B and HCV--response to infection and treatment.Genomic variation-guided management in chronic hepatitis C.Systematic review: Asian patients with chronic hepatitis C infection.Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis.Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients.IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C.Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies.Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy.Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.Hepatitis C virus and lipid profiles: more questions than answers?Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications.Reply to Guedj et al.: Early transient increase of hepatitis C virus viral load in genotype 1 and 2 infections, and the use of mathematical modeling.Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study

P2860

Q28478310-87AE1BA1-B9C8-4EB9-AB56-B9D5BC7994F0 Q30828421-FCDFE32F-0A5B-4875-86EB-0186B92F82B2 Q34251341-202154E6-CE1C-425E-846E-98A6E9C5AE51 Q34348799-B0B5B8BA-E111-402D-87DA-75E0C22B273F Q34539324-CB71AA64-6FBF-4A03-BFDA-D57D0DB9CDD6 Q34604371-FACB2F6D-F76B-4ACB-8D64-1C1E6351255E Q34734013-3F1FA3E2-C9C0-4D1D-B599-EE12C173BBF8 Q36208380-24D9A57E-CFEF-405B-AD3E-E158DFF565A7 Q36224697-DD7A5409-3417-474D-B68E-BE8277B8E3B4 Q36666366-F7783390-203D-4F61-AF19-D8E8E2AF0793 Q36766899-0D917C12-BCC1-48C6-B9F4-C7F8179A39E4 Q37138516-3606DD7D-5042-4A34-8D3F-B4B45BC7E9AA Q37208941-7EE7A51E-2502-4483-AB49-E210601F472F Q37352305-F2339D15-82BF-423F-9D33-A94921D729AA Q37654502-E4236DDC-5DA7-494D-8776-D6D5C5048BDA Q37929753-54BDEA94-0031-4AAA-BCB9-3DBFDB65EA27 Q38003346-630923A0-D6A1-4560-BCC6-2CE99A9EE325 Q38003354-46FE5A8B-DD77-4B77-A551-EB3804613701 Q38013941-8C0FD0B3-EC3F-424C-9855-46697A24BB50 Q38038693-EC4D1B6E-519D-4F51-B836-E01A776AA89C Q38096012-C6205F00-947D-4824-BCB6-6D521137C029 Q38204741-9D450546-B315-463C-AA1F-C5FF859E8398 Q38445623-231A25A6-6646-474D-B997-1B8DCF397062 Q40027212-3B063A73-2237-4B52-AB95-AAD09F30CEAB Q40707628-28F91D99-30D8-444A-81D2-E830A3F914C1 Q41503237-E8B2780C-0FD9-4F26-9206-1BE7EE3B7F3C Q42256205-499B482D-22F8-49F5-B844-442563800794 Q42288046-2835611E-7043-4B07-A309-75A598D74176 Q42837685-CD131068-CF33-41EE-AE5C-0F5C1AAC41CF Q43048075-F6B3497F-DD9E-46B7-95F6-CDC3CFB9B7E2 Q44983621-BB8D73B4-4BA5-4C13-BCCD-70FA0C788A51 Q50555301-9B227CEC-88A6-4A2D-88F5-F89A301A7080 Q52589911-BCA9E7E1-F056-496B-B933-EFBFA832C03E Q55631548-061B576F-8CF9-4195-BCC6-14A638569553 Q57213193-663BADB8-6DD9-4BC5-B5E6-F6262BF61D07

P2860

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.

http://www.wikidata.org/entity/Q34621423

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@ast

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@en

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@nl

type

label

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@ast

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@en

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@nl

prefLabel

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@ast

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@en

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@nl

P1433

Q34621423-97F1734E-A2C2-4A3E-845E-1264F186E8CF

P1476

Q34621423-4602CCC8-A41E-48BF-9F72-96E286F68A43

P2093

Q34621423-06E06209-7E10-4873-8236-2B05D6F90F43

Q34621423-171723E7-C6DC-4B17-AEA4-1317EE481B7D

Q34621423-24A916A6-2071-4D16-B464-F598CF3A9781

Q34621423-5AF53B76-B8F0-48BF-9488-BC198267788F

Q34621423-8F2D5B10-7E87-4F51-948B-33604D9F56FD

Q34621423-B62D7805-3DB7-47E1-A1B4-35D69D48C1EA

Q34621423-CE036A21-9C03-4999-8BFE-7439C65819FC

Q34621423-D4724CC7-0AC6-4371-90E6-4C93FBEEE286

Q34621423-D63BDEC5-6106-4BDF-AA6C-7D16AC8A4426

Q34621423-DEE84FF0-9D66-42AF-B7E7-5C7F12EC0DBB

P2860

Q34621423-0E005478-29BA-4B97-B9B3-5E755A059F85

Q34621423-115C3A03-1067-4D8A-A0CB-F85F5F26B641

Q34621423-15E4F718-6E1D-4D25-A5FB-2E7ED8481D29

Q34621423-17ACB23E-3158-48FD-80C4-36099B09AED6

Q34621423-18A1695F-C137-4B56-946E-8E4AA8D04EB6

Q34621423-31F1A2F9-26DA-4A22-AA3C-E15F1BCE9DE6

Q34621423-406AD916-60DC-4448-B3D4-E1A7994E2269

Q34621423-42A5AC01-A762-45A3-8A18-C3C224730625

Q34621423-45D3F7CB-1B1C-40E3-A8D0-DA8789B16DE6

Q34621423-47CC365A-E6DD-4F53-B7B5-3DCA093DBB74

P304

Q34621423-757A74F2-9436-4748-BF3B-35B81D673149

P31

Q34621423-9C8BCBF5-2FC6-4677-8A22-A97E8DF61A48

P356

Q34621423-AA42492E-3835-418E-9047-53C80F0A9444

P407

Q34621423-ED50232F-AEE0-425B-83FD-BF22684715CA

P433

Q34621423-82A8927D-50AD-4581-9E45-B2E83E448899

P478

Q34621423-0D948138-AA45-48E2-86C8-673A0C23F0BB

P577

Q34621423-9E1658D9-1A9F-411B-9461-3E33EB9F4173

P5875

Q34621423-A807D0B7-CEA8-4F1F-B609-71B7531F6E4A

P698

Q34621423-7DADE80F-E0BE-497D-8C52-5A07BEFA6ADE

P932

Q34621423-BC56EEA6-8E04-4413-9E0A-7425B547639F

P356

PNAS.1100349108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Association of IL28B gene vari ...... th IFN plus ribavirin therapy.

@en

P2093

Chen-Hua Liu

http://www.w3.org/2001/XMLSchema#string

Ching-Sheng Hsu

http://www.w3.org/2001/XMLSchema#string

Chun-Jen Liu

http://www.w3.org/2001/XMLSchema#string

Ding-Shinn Chen

http://www.w3.org/2001/XMLSchema#string

Hung-Chia Chen

http://www.w3.org/2001/XMLSchema#string

Jenher Jeng

http://www.w3.org/2001/XMLSchema#string

Jia-Horng Kao

http://www.w3.org/2001/XMLSchema#string

Ming-Yang Lai

http://www.w3.org/2001/XMLSchema#string

Pei-Jer Chen

http://www.w3.org/2001/XMLSchema#string

Shih-Jer Hsu

http://www.w3.org/2001/XMLSchema#string

P2860

IL-28, IL-29 and their class II cytokine receptor IL-28R

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity

New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a

Lambda interferon inhibits hepatitis B and C virus replication.

Estimation of dynamical model parameters taking into account undetectable marker values

Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

P304

3719-3724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1100349108

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49836193

http://www.w3.org/2001/XMLSchema#string

P698

21321200

http://www.w3.org/2001/XMLSchema#string

P932

3048137

http://www.w3.org/2001/XMLSchema#string